Clinical Trial Update: An International Study of Rimonabant in Dyslipidemia With AtheroGenic Risk In Abdominally Obese Patients [Phase 3]

View source ↗

Summary

An international Phase 3 trial evaluating rimonabant for dyslipidemia with atherogenic risk in abdominally obese patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Obesity

Drugs mentioned

• Rimonabant (rimonabant)

Snippet

Sponsor: Sanofi | Conditions: Dyslipidemia, Obesity | Phase 3 | Status: COMPLETED